| 赵天祥,黄世明,吴共国,陈卫仙,朱俊,陈善明.培美曲塞与贝伐珠单抗治疗老年肺腺癌患者的效果与安全性评价[J].中国临床保健杂志,2020,23(4):510-513. |
| 培美曲塞与贝伐珠单抗治疗老年肺腺癌患者的效果与安全性评价 |
| Efficacy and safety of pemetrexed and bevacizumab in the treatment of elderly patients with lung adenocarcinoma |
| 投稿时间：2020-03-17 |
| DOI：10.3969/J.issn.1672-6790.2020.04.018 |
| 中文关键词: 肺腺癌 培美曲塞 贝伐单抗 治疗结果 老年人 |
| 英文关键词: Adenocarcinoma of lung Pemetrexed Bevacizumab Treatment outcome Aged |
| 基金项目:浙江省杭州市科技发展计划项目(2018NY04) |
|
| 摘要点击次数: 4587 |
| 全文下载次数: 5633 |
| 中文摘要: |
| 目的 评价培美曲塞与贝伐珠单抗治疗老年肺腺癌患者的疗效与安全性。方法 选取本院2019年1月到2020年1月诊治的88例老年肺腺癌患者,根据不同治疗方案分为对照组与观察组,每组44例；两组均予以铂类方案化疗,同时对照组予以培美曲塞治疗(静滴,500 mg/m2,治疗后第1天),观察组予以培美曲塞与贝伐珠单抗治疗(静滴培美曲塞,500 mg/m2,治疗后第1天；静滴贝伐珠单抗,7.5 mg/kg,治疗后第1天)；治疗后对比两组的临床疗效、生命质量(QLQ-C30评分)、肿瘤标志物(肿瘤特异性生长因子、癌胚抗原、细胞角蛋白19)以及不良反应发生情况(疲劳、脱发、血糖升高、转氨酶升高)。结果 观察组的局部控制率与总有效率(63.6%、81.8%)均高于对照组(40.9%、61.4%),P<0.05；观察组治疗后QLQ-C30问卷的整体功能评分[(65.9±6.1)分]高于对照组[(54.7±5.4)分],且特异症状评分[(17.8±3.9)分]低于对照组[(25.3±3.2)分],P<0.05；观察组治疗后的肿瘤特异性生长因子、癌胚抗原、细胞角蛋白19[(60.7±12.1)μg/L、(92.6±8.8)μg/L、(124.7±10.2)μg/mL]均低于对照组[(79.4±10.5)μg/L、(112.8±11.3)μg/L、(149.2±7.8)μg/mL)],P<0.05；观察组的不良反应发生率(31.8%)与对照组(27.3%)相当,P>0.05。结论 培美曲塞与贝伐珠单抗治疗老年肺腺癌患者的总有效率高,可明显改善患者的生命质量,降低肿瘤标志物水平；与单纯培美曲塞治疗不良反应相当。 |
| 英文摘要: |
| Objective To evaluate the efficacy and safety of pemetrexed and bevacizumab in the treatment of elderly patients with lung adenocarcinoma,in order to explore the effective treatment of the disease.Methods 88 elderly patients with lung adenocarcinoma diagnosed and treated in our hospital from January 2019 to January 2020 were divided into control group and observation group according to different treatment plans,44 cases in each group;both groups were treated with platinum chemotherapy,while the control group was treated with pemetrexed (intravenous drip,500 mg/m2,d1),and the observation group was treated with pemetrexed and bevacizumab (intravenous drip pemetrexed,500mg/m2,d1) After treatment,the clinical efficacy,quality of life (QLQ-C30 score),tumor markers (tumor specific growth factor,carcinoembryonic antigen,cytokeratin 19) and adverse reactions (fatigue,hair loss,blood glucose rise,transaminase rise) were compared between the two groups.Results The local control rate and total effective rate (63.6%,81.8%) in the observation group were higher than those in the control group (40.9%,61.4%),P<0.05;the overall function score (65.9±6.1) in the observation group after treatment was higher than that in the control group (54.7±5.4),and the specific symptom score (17.8±3.9) was lower than that in the control group (25.3±3.2),P<0.05;the tumor specific growth factor,carcinoembryonic antigen,cytokeratin 19 [(60.7±12.1)μg/L,(92.6±8.8)μg/L,(124.7±10.2)μg/mL] in the observation group were lower than those in the control group [(79.4±10.5)μg/L,(112.8±11.3)μg/L,(149.2±7.8)μg/mL),P<0.05;the incidence of adverse reactions in the observation group (31.8%) was similar to that in the control group (27.3%),P>0.05.Conclusion Compared with pemetrexed alone,pemetrexed and bevacizumab can improve the quality of life and reduce the level of tumor markers in the elderly patients with lung adenocarcinoma,which has similar adverse reactions.The clinical efficacy and safety are higher,and it is worth carrying out. |
|
查看全文
|
| 关闭 |
|
|
|